SER: Rasio Kapitalisasi Pasar marang Nilai Buku Serina Therapeutics Inc

Tandha merek Serina (SER)

The Serina Therapeutics, Inc. (SER) price chart on the GURU.Markets platform shows quotes for the company, which utilizes AI and robotics to automate polymer modification within the POZ system. The current figure is 2.55. The business is currently executing a clinical trial plan for Parkinson's disease drugs following an asset merger. The development of brain disease therapies relies on partnerships with scientific centers.

Serina Therapeutics, Inc. (SER) - Rasio Kapitalisasi Pasar marang Nilai Buku saka 28.03.2024 nganti 30.10.2026

Rincian analitis lan laporan data perusahaan Serina Therapeutics Inc (SER)

- nilai pasar lan prakiraan target analis:
Bagan rega Serina Therapeutics, Inc.|SER - Bagan tingkat prakiraan
- informasi kapitalisasi pasar:
Kapitalisasi pasar Serina|SER - Nilai Dipunlarasaken Utang lan Kas
- indikator nilai aset resik miturut neraca:
Nilai Buku saben Saham Serina Therapeutics|SER - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku serinatherapeutics.com|SER - Nilai Agregat Aset
- rincian struktur utang lan likuiditas bisnis:
Utang marang Ekuitas Serina Therapeutics, Inc.|SER - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Serina|SER - Gunggung utang perusahaan|Utang marang nilai buku Serina|SER - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Serina Therapeutics|Rasio cepet serinatherapeutics.com
- indikator bathi lan kelipatan valuasi:
SER - Penghasilan resik perusahaan
Analisis wiwitan perusahaan:Serina Therapeutics, Inc., SER
Produk asil prodhuksi Serina Therapeutics Inc

Institutional capital assesses the attractiveness of Serina Therapeutics, Inc. (SER) through a premium over the net asset value. This price-to-book ratio determines the price the market is willing to pay per unit of equity. A high coefficient reflects growth expectations for polymer drug delivery platforms. The chronic nature of Parkinson's pathologies ensures steady demand, justifying the premium over book value. However, a significant divergence of quotes from asset value reduces the defensive margin of safety.

Karo sapa Serina Therapeutics, Inc. saingan

Jazz Pharmaceuticals (JAZZ) - Rasio Nilai Pasar marang Nilai Buku|Kapitalisasi Pasar marang Aset Bersih CYTK (cytokinetics.com)|PTCT (PTC Therapeutics) - Rasio Kapitalisasi Pasar marang Nilai Buku|SRRK: Nilai Pasar marang Nilai Buku|Rasio Kapitalisasi Pasar marang Nilai Buku CNTA|Rasio Kapitalisasi Pasar marang Nilai Buku Dyne Corp (DYN)|Rasio Nilai Pasar marang Nilai Buku Edgewise Therapeutics EWTX|Nilai Pasar marang Nilai Buku RAPP|ALMS - Rasio Nilai Pasar marang Nilai Buku|Zevra Therapeutics Inc (ZVRA) - Rasio Kapitalisasi marang Aset Bersih|CTNM: Rasio Kapitalisasi Pasar marang Nilai Buku|Larimar Corp (LRMR) - Rasio Kapitalisasi Pasar marang Nilai Buku|Rasio Kapitalisasi marang Aset Bersih CAPR|TRDA: Nilai Pasar marang Nilai Buku|Rasio Nilai Pasar marang Nilai Buku Channel Therapeutics Corp (PTHS)|medicinova.com - Rasio Kapitalisasi marang Nilai Buku|Rasio Kapitalisasi Pasar marang Nilai Buku BTAI (BioXcel)|ProMIS Neurosciences Inc. (PMN) - Koefisien Nilai Pasar marang Nilai Buku|APUS: Rasio Kapitalisasi marang Aset Bersih|AEON - Rasio Kapitalisasi Pasar marang Nilai Buku|nlspharma.com (NLSP) - Rasio Nilai Pasar marang Nilai Buku|Bionomics - Nilai Pasar marang Nilai Buku|Rasio Nilai Pasar marang Nilai Buku FSD Pharma Inc.|Koefisien Nilai Pasar marang Nilai Buku Reata Pharma RETA